In addition to these biologics, small-molecule-receptor tyrosine kinase inhibitors (RTKIs) targeting VEGF receptors (VEGFR1VEGFR3) and other kinase signalling pathways have been extensively investigated as anti-angiogenics and several have progressed to the market.